Alnylam Pharmaceuticals (ALNY) Free Cash Flow Growth (3y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) Free Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
24.91% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
20.11% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
14.71% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Alnylam Pharmaceuticals |
37.04 Bn |
34.03 Bn |
959.66 Mn |
31.42% |
| Date | Value |
|---|
| Mar 31, 2026 |
31.42% |
| Dec 31, 2025 |
53.50% |
| Sep 30, 2025 |
61.71% |
| Jun 30, 2025 |
45.53% |
| Mar 31, 2025 |
10.36% |
| Dec 31, 2024 |
1.71% |
| Sep 30, 2024 |
28.51% |
| Jun 30, 2024 |
42.22% |
| Mar 31, 2024 |
29.88% |
| Dec 31, 2023 |
32.21% |
| Sep 30, 2023 |
68.56% |
| Jun 30, 2023 |
21.01% |
| Mar 31, 2023 |
12.12% |
| Dec 31, 2022 |
7.46% |
| Sep 30, 2022 |
15.53% |
| Jun 30, 2022 |
-37.99% |
| Mar 31, 2022 |
3.79% |
| Dec 31, 2021 |
24.87% |
| Sep 30, 2021 |
-7.30% |
| Jun 30, 2021 |
-4.47% |
